Greenlight Analytical is seeking investment funds to procure and fit-out office, lab, and manufacturing space; design, develop and release four products to the market; recruit a sales and marketing team, and implement business operations and controls to ensure compliance with quality management systems as well as test calibration laboratory controls. More information can be found on Gust.

The unparalleled analysis capability of Greenlight Analytical’s mass spectrometer, combined with customized application software and a simplified user interface enables a line of instruments that can detect toxins, residual pesticides and fertilizers, mould precursors, and other regulated chemicals that can be operated by non‐experts. In addition to the emerging medical and recreational cannabis markets, Greenlight Analytical’s line of narcotics analyzers can help combat the over 100,000 deaths4 caused by opioid and fentanyl abuse by providing clinicians with the tools they need to respond quickly to medical emergencies (overdoses).

Greenlight Analytical will provide law enforcement, healthcare, and the emerging cannabis markets with advanced, portable mass spectrometers. Our analyzers will ensure product safety and consistency, empower medical personnel with critical information to save lives and provide government regulators and revenue enforcement agencies with tools to ensure compliance with tax and supply chain regulations.

The value of the medical cannabis industry in Canada is over $2B annually¹.  With the legalization of recreational cannabis in 2018, the value of the recreational cannabis market is in excess of $5B². Product testing to conform to Government regulations accounts for over $1.5B annually in lost product due to failed testing³.

Greenlight Analytical Executive Summary

These documents contain “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information is disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action. This forward-looking information is based on current expectations, estimates and assumptions concerning future events and is subject to a number of uncertainties and factors, many of which are outside the company’s control, which could cause actual results to differ materially from those described in the forward-looking information. No assurance can be given that any of the events anticipated by the forward-looking information will transpire or occur or, if any of them do so, what benefits will be derived therefrom. Shareholders, potential shareholders, financing institutions and other readers are urged to consider these factors carefully in evaluating the forward-looking information which speak only as of the date made. Except as may be required by law, the company expressly disclaims any intention or obligation to revise or update any forward-looking information and information whether as a result of new information, future events or otherwise.